{
    "clinical_study": {
        "@rank": "97538", 
        "acronym": "SEATH", 
        "arm_group": [
            {
                "arm_group_label": "As2O3", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be treated with TACE containing As2O3"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether transarterial chemoembolization containing\n      arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular\n      carcinoma."
        }, 
        "brief_title": "Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC", 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  accordance with primary hepatocellular carcinoma diagnosis standard\uff1acytohistology\n             standard or non-invasive standard.1\uff09+2\uff09a or 1\uff09+2\uff09b+3\uff09of the following are the\n             non-invasive diagnosis criteria:(1)patients with HBV or HCV related liver\n             cirrhosis.(2)radiological lesion(s) in liver with arterial hypervascularity and\n             venous or delayed phase washout: a.one kind of imaging technology diagnosis for those\n             with lesions>2cm;b.two kinds of imaging technology obtains the consistent conclusion\n             for lesions with diameter of 1-2 cm.(3)serum AFP level \u2265400 ug/L lasting for more\n             than 1 month or \u2265200 ug/L lasting for more than 2 months, other diseases that may\n             cause the AFP level increase can be excluded,such as pregnancy, genital or embryonic\n             tumors and active hepatitis.\n\n          -  age of 18 to 75 year,male or female\n\n          -  life expectancy of 12 weeks\n\n          -  Barcelona  Clinic  Liver  Cancer (BCLC)stage B\n\n          -  laboratory tests:(1)leukocyte>3*19^9/L;(2)hemoglobin\u22658.5g/dl;(3)platelet count\n             \u226550*10^9/L,(4)ALT and AST were less than three times the normal limit;(5)albumin \u2265\n             3.0 g/dl;(6)total bilirubin acuities 3 mg/dl;(7)prothrombin time international\n             standardization ratio (PT - INR) < = 2.3 or prothrombin time (PT)more than normal\n             compared 3 seconds;(8)serum creatinine is less than 1.5 times the normal of the upper\n             limit\n\n          -  patients with signed informed consent\n\n        Exclusion Criteria:\n\n          -  concomitant malignancies distinct from HCC currently or previously\n\n          -  allergic to subject agent(such as arsenic) or other agent related to the trial\n\n          -  BCLC stage 0,A,C or D\n\n          -  HCC accounting for the 70% of the liver size or more\n\n          -  liver function Child-Pugh score of C\n\n          -  ECOG score of 1 or higher\n\n          -  severe heart diseases,such as congestive heart failure with cardiac function of New\n             York Heart Association(NYHA)functional class II or severe, active coronary\n             disease(except for who with myocardial infarction for more than 6 months) and cardiac\n             arrhythmia needing medical management(except for that controllable by\n             \u03b2-blockers\u3001calcium channel blockers and digoxin )\n\n          -  uncontrollable hypertension(diastolic blood pressure cannot be controlled below 90\n             mmHg even after antihypertension treatment by antihypertensive drugs).\n\n          -  active severe infection(grade 2 or higher according to NCI-CTCAE version 4.0)\n\n          -  active tuberculosis or pulmonary tuberculosis cannot be excluded\n\n          -  CNS malignancies, including intracranial metastases\n\n          -  gastrointestinal bleeding with clinical findings in the previous 30 days\n\n          -  chronic renal failure\n\n          -  pregnancy or breastfeeding\n\n          -  any other unstable conditions or circumstances possibly to jeopardise the safety or\n             compliance of the subjects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018757", 
            "org_study_id": "2012AA022701"
        }, 
        "intervention": [
            {
                "arm_group_label": "As2O3", 
                "description": "transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol", 
                "intervention_name": "TACE containing As2O3", 
                "intervention_type": "Drug", 
                "other_name": "transarterial chemoembolization,TACE,As2O3,arsenious acid"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol", 
                "intervention_name": "TACE containing placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Arsenic trioxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Carcinoma, Hepatocellular", 
            "primary liver cancer", 
            "primary hepatocellular carcinoma", 
            "transarterial chemoembolization", 
            "Chemoembolization, Therapeutic", 
            "arsenic trioxide", 
            "arsenous anhydride", 
            "diarsenic trioxide", 
            "randomized controlled trial", 
            "multicenter study", 
            "HCC", 
            "TACE"
        ], 
        "lastchanged_date": "May 25, 2014", 
        "link": [
            {
                "description": "Chinese Clinical Trial Registry", 
                "url": "http://www.chictr.org/cn/"
            }, 
            {
                "description": "National Health and Family Planning Commission of the People's Republic of China", 
                "url": "http://www.nhfpc.gov.cn/"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Sun Yat-sen University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Peihong Wu, MD,PHD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gaojun Teng, MD,PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "Zhongda Hospital Southeast University"
                }, 
                "investigator": {
                    "last_name": "Gaojun Teng, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning", 
                        "zip": "110001"
                    }, 
                    "name": "The First Hospital of China Medical University"
                }, 
                "investigator": {
                    "last_name": "Haibo Shao, MD,PHD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi"
                    }, 
                    "name": "Xijing Hospital\uff0cFourth Military Medical University"
                }, 
                "investigator": {
                    "last_name": "Guohong Han, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Zhongshan Hospital Fudan University"
                }, 
                "investigator": {
                    "last_name": "Jianhua Wang, MD,PHD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "haiboshao@aliyun.com", 
            "last_name": "Haibo Shao, MD,PHD", 
            "phone": "862483282730"
        }, 
        "overall_official": {
            "affiliation": "China Medical University, China", 
            "last_name": "Haibo Shao, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "time to progression", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of first documented progression, up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018757"
        }, 
        "responsible_party": {
            "investigator_affiliation": "First Hospital of China Medical University", 
            "investigator_full_name": "Haibo Shao", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "patients proportion of CR and PR according to mRECIST", 
                "measure": "objective response rate", 
                "safety_issue": "No", 
                "time_frame": "every 3 months from randomization until the date of first documented progression, up to 24 months"
            }, 
            {
                "description": "survival from randomization to the date of first documented progression according to the mRECIST criterion", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of first documented progression, up to 24 months"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of death from any cause, up to 60 months"
            }, 
            {
                "measure": "Proportion of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "every 3 months from  randomization until the date of first documented progression, up to 24 months"
            }
        ], 
        "source": "First Hospital of China Medical University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Sun Yat-sen University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Zhongda Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fudan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xijing Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "First Hospital of China Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}